Daniel Ebner
Group Head / PI and Member of congregation
The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.
The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens
Recent publications
-
Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models
Journal article
Rodriguez-Berriguete G. et al, (2023), Clinical Cancer Research
-
A genome-wide CRISPR screen identifies CALCOCO2 as a regulator of beta cell function influencing type 2 diabetes risk.
Journal article
Rottner AK. et al, (2022), Nature genetics
-
Minimalised Three-Dimensional Human Midbrain In Vitro Model for Neurotoxicity Evaluation of DYRK1 Inhibitors
Preprint
Wan X. et al, (2022)
-
Small-molecule Polθ inhibitors provide safe and effective tumor radiosensitization in preclinical models
Preprint
Rodriguez-Berriguete G. et al, (2022)
-
SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection
Journal article
Wei J. et al, (2022), Nature Communications, 13